The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children With Nocturnal Enuresis

Abstract

Data suggest that there is a decreased risk of hyponatremia with oral desmopressin compared with intranasal desmopressin. Identifiable and preventable risk factors for hyponatremia are inappropriately high fluid intake, administration of a larger than recommended dose, young age (less than 6 years) and concomitant administration of another medication. When desmopressin is prescribed, patients should be instructed to avoid high fluid intake when the medication is ingested, not ingest a higher than recommended dose and promptly discontinue the medication and seek assessment if headache, nausea or vomiting develops.

Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: A retrospective study of switching from intranasal desmopressin

“…time they should also note that therapy with desmopressin ODT should be initiated with the minimal possible dose administered once daily [23].…”

Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children

“…Until now, DDAVP is the only drug therapy with evidence level 1, grade A recommendation, for the indication of monosymptomatic nocturnal enuresis (MNE) [4]. Reported adverse events are generally described as mild, and include headache, abdominal pain, nausea, and -typically for the nasal spray [5] -nasal epistaxis, and congestion/rhinitis. Hyponatremia remains an infrequent but very serious adverse event associated with the antidiuretic effect of DDAVP treatment [6].…”

Enuresis in pediatric practice

“…К настоящему времени разработана подъязычная (рас-творимая) форма Минирина® -таблетки по 60 и 120 мкг, которая рекомендуется Европейским медицинским агентством в качестве средства выбора для применения в педиатрической практике. Препарат удобен в исполь-зовании и обладает стабильной фармакокинетикой [82]. Исследование детей с моносимптомным энурезом и СДВГ показало, что высокая эффективность монотера-пии Минирином® связана не только с его действием на уровне почечных канальцев, но и с положительным влиянием на функциональное состояние ЦНС [83].…”